



PATENT  
22851-033

APPLICATION FOR UNITED STATES PATENT

for

FUSION PROTEINS FOR TARGETED DELIVERY OF ANTIMICROBIAL  
PEPTIDES

in the names of

WENYUAN SHI  
MAXWELL H. ANDERSON  
SHERIE L. MORRISON  
KHAM TRINH  
LETITIA WIMS  
LI CHEN

prepared by

MANATT, PHELPS & PHILLIPS, LLP

DOCKET 22851.033

This application is a continuation-in-part of United States patent application serial number 09/378,577 filed August 20, 1999.

**Field of the Invention:**

This invention relates to targeted delivery of antimicrobial peptides by fusion proteins. More specifically, this invention relates to a fusion protein comprising a recognition sequence and an antimicrobial peptide. The fusion proteins of the present invention are useful for specifically and selectively destroying or inhibiting the growth of microbial organisms that are associated with parasitic infestations as well as bacterial, rickettsial, protozoan and fungal infections, especially in a complex multi-species environment.

**Background of the Invention:**

The Centers for Disease Control estimates that half of the more than 100 million annual prescriptions of antibiotics are unnecessary. As a result, microbes have, in many cases, adapted and are resistant to antibiotics due to constant exposure and improper use of the drugs. It is estimated that the annual cost of treating drug resistant infections in the United States is approximately \$5 billion. This continued emergence of anti-microbial-resistant bacteria, fungi, yeast and parasites has encouraged efforts to develop other agents capable of killing pathogenic microbes.

Recent research has revealed a class of naturally occurring antimicrobial peptides in humans, other mammals, insects and other organisms. Anti-microbial peptides are usually expressed by various cells in the body including neutrophils and epithelial cells. In mammals, including man, antimicrobial peptides are found on the surface of the tongue, trachea, and upper intestine. Naturally occurring anti-microbial peptides are generally amphipathic molecules that contain fewer than 100 amino acids. Many of these peptides generally have a net positive charge (i.e., cationic) and most form helical structures. Again, speaking generally, the peptides' antimicrobial efficacy is in their

ability to penetrate and disrupt the microbial membranes, thereby killing the microbe or inhibiting its growth.

One example of an anti-microbial peptide is histatin. Histatin, and related derivative peptides, posses antifungal and antibacterial activity against a variety of organisms, including *Streptococcus mutans*. MacKay, B.J. et al., Infect. Immun. 44:695-701 (1984); Xu, et al., J. Dent. Res. 69:239 (1990). *S. mutans* is believed to be the principal cause of dental caries (tooth decay) in man.

A negative aspect of treatment with antibiotics or anti-microbial peptides is their ability to kill or inhibit the growth of a broad spectrum of organisms. The human body is home to perhaps millions of different bacteria, many of which are vital for optimum health. Overuse of antibiotics can seriously disrupt the normal ecology of the body and render humans more susceptible to bacterial, yeast, viral, and parasitic infection. This effect is also seen with administration of anti-microbial peptides. For example, while histatin has been shown to kill the bacterium primarily responsible for dental caries, general administration of histatin can actually stimulate the growth of oral yeast and other bacteria, such as *Actinomyces sp.* Accordingly, histatin is not useful by itself for prevention of dental disease.

Another disadvantage of administration of antimicrobial peptides is their ability to damage host cells at higher concentrations since these positively charged peptides can also penetrate and disrupt eukaryotic cell membranes.

Previous efforts to target delivery of pharmaceutically active agents relied principally on non-specific chemical reactions between a pharmaceutically active agent, and a targeting component. For example Shih et al. United States patent 5,057,313 refers to targeting delivery of drugs, toxins and chelators to specific sites in an organism by loading a therapeutic or diagnostic component onto a polymeric carrier, followed by conjugation of the carrier to a targeting antibody. Hansen, United States patent 5,851,527 claims a similar invention. A drawback to this approach is that the non-specific linkage of the pharmaceutical reagents to unknown sites on the antibody molecule used for targeting may interfere with delivery of the therapeutic agents. See Rodwell et al., United

States patent 4,671,958. Moreover, chemical modification of a targeting antibody by the nonspecific reactions during conjugation may substantively alter the antibody itself, thereby affecting its binding to targets. Chemical linkage is very inefficient, and the result is non-uniform, making the technique very difficult to use in practice.

More recently, there have been a number of reports of the use of recombinant techniques to produce fusion proteins for the treatment of disease. *See* Penichet and Morrison, *J. Immunological Methods*, 248:91-101 (2001) for review. Penichet et al. discuss efforts to treat malignant disease using a genetically engineered protein construct including an immunological component that binds specifically to tumor cells and a cytokine capable of eliciting significant antitumor activity. *See, e.g.* Pastan et al. United States patent 5,981,726, and Fell, Jr. et al., United States patent 5,645,835.

However, to date there have not been any reports of directing antimicrobial agents to affected regions of humans or animals using target-specific molecules.

### **Summary Of The Invention**

Microbial infection may be treated by administration of a fusion protein comprising one or more recognition sequences and at least one antimicrobial peptide. In preferred embodiments, a linker peptide connects the recognition sequence and one or more antimicrobial peptides. The recognition sequence may be an immunoglobulin molecule, or fragment thereof, that specifically binds to a target antigen present on a pathogen. The recognition sequence may also be a non-immunological polypeptide, providing that the polypeptide binds specifically to a particular ligand. In presently preferred embodiments the recognition sequence is monoclonal antibody that binds specifically to *S. mutans* and the antimicrobial peptides are derivatives of histatin.

### **Brief Description of the Drawings**

The present invention is now described, by way of illustration only, in the following examples which refer to the accompanying FIGS. 1-4, in which:

FIG. 1 is a schematic diagram of the sequential PCR reactions used to assemble the heavy chain portion of the antibody-based fusion protein.

FIG. 2 shows the DNA sequences (SEQ ID NOS: 9-15) of the primers used in the sequential PCR reactions in embodiments of the present invention.

FIG. 3 shows the DNA sequence (SEQ ID NO: 1) encoding the anti-microbial peptide, histatin 5, the linker peptide, and the variable region of the heavy chain derived from the SWLA3 monoclonal antibody together with the predicted amino acid sequence (SEQ ID NO: 4) of an embodiment of the present invention.

FIG. 4 shows the DNA sequence (SEQ ID NO: 5) encoding the anti-microbial peptide, dhvar 1, the linker peptide, and the variable region of the heavy chain derived from the SWLA3 monoclonal antibody together with the predicted amino acid sequence (SEQ ID NO: 8).

#### **Detailed Description Of The Invention**

##### **1. Structure Of The Fusion Proteins**

In various embodiments of the invention, the fusion protein for targeted delivery of antimicrobial peptides comprises at least one recognition sequence that specifically recognizes and binds to a microbe specific antigen. In a presently preferred embodiment of the invention, recognition sequences are derived from SWLA3, a monoclonal antibody that specifically binds to an antigen present on *S. mutans*. The fusion protein of the present invention further comprises an anti-microbial peptide that is toxic to one or more selected microbes. Preferably, the fusion protein also includes one or more linker peptides connecting the recognition sequences and antimicrobial peptide sequences.

The fusion protein of the present invention includes a recognition sequence that provides for specific targeting. Specific targeting provides for greater concentrations of the antimicrobial peptide at sites where antimicrobial therapy is needed. Thus the present invention can be administered at concentrations that will effectively kill or inhibit growth of harmful microbes, which are low enough to spare the beneficial microbes located

elsewhere. As shown in the accompanying examples, a fusion protein according to the present invention comprising histatin 5 or dhvar 1 (both histatin derivatives) a glycine/serine linker peptide, and the SWLA3 variable region has specific anti-microbial activity and antigen specificity against *S. mutans*.

The linker sequence is expected to facilitate the correct conformation of the recognition sequence and antimicrobial peptides. In addition, by providing flexibility, the linker sequence may be expected to allow antimicrobial peptides to act on microbial membranes.

The present invention provides for dimeric immunoglobulin molecules as well as monomeric or multimeric molecules comprising fusion proteins for targeted delivery of antimicrobial peptides. Further, immunoglobulin fragments that contain enough of the variable region structure to allow for specific antigenic binding may be used in the practice of the invention.

In a preferred embodiment, the immunoglobulin portion of the fusion protein is at least a portion of chimeric antibody whose variable region is derived from a monoclonal antibody that specifically binds to a microbe, and whose constant region is capable of engaging the humoral immune effector systems of the animal to be treated. When the mammal to be treated is human, the constant region is preferably of the IgG or IgM isotypes. Preparation and use of such chimeric monoclonal antibodies is disclosed and claimed in United States patent 6,231,857 and pending United States applications 09/378,577 and 09/881,823. Use of a chimeric antibody for targeting may provide additional antimicrobial efficacy by engaging the host's humoral immune system.

The fusion proteins of the invention include other anti-microbial peptides. Anti-microbial peptides within the scope of the present invention indolicidin, apidaecin, bacteriocin,  $\alpha$ -helical clavanin, magainin, cecropin, andropin, histatin,  $\beta$ -pleated sheet bacteriocin dodecapeptide, tachyplesin, protegrin, defensin,  $\beta$ -defensin,  $\alpha$ -defensin (Miyasaki and Lehrer, 1998, *Intl. J. Antimicrobial Agents* 9:270-272); alexomycin (Marshel and Jones, 1999, *Diagn. Microbiol. Infect. Dis.* 33:183-184); nisin, ranalexin, buforin (Giacometti et al., 1999, *Peptides* 30:1266). Derivatives and analogues of such

peptides are likewise within the scope of the present invention. The relatively simple structure of bacteriocidal peptides lends itself to designing a peptide with increased anti-microbial activities and decreased host cell toxicity.

More specifically, buforin, nisin and cecropin have antimicrobial effects on *Escherichia. coli*, *Shigella disenteriae*, *Salmonella typhimurium*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*.

Magainin and ranalexin have antimicrobial effects on the same organisms, and in addition has such effects on *Candida albicans*, *Cryptococcus neoformans*, *Candida krusei*, and *Helicobacter pylori*.

Protegrin has antimicrobial effects on *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Haemophilus influenzae*.

Alexomycin has antimicrobial effects on *Camphylobacter jejuni*, *Moraxella catarrhalis* and *Haemophilus influenzae*.

$\alpha$  defensin and  $\beta$  pleated sheet defensin have antimicrobial effects on *Streptococcus pneumoniae*.

In additional embodiments, the antibody fusion proteins of the invention may be directed toward antigens associated with other infectious agents including, rickettsia, fungi, protozoa, and parasites.

The present invention offers the advantage of targeted delivery of antimicrobial peptides, which allows for a lower concentration of anti-microbial peptide to be administered thereby substantially decreasing unintended exposure. Thus side effects due to drug toxicity and unintended exposure of non-pathogenic organisms, including bacteria, may be avoided. In addition, the targeted antimicrobial fusion protein is expected to be readily metabolized by the body because it is based on substances that occur naturally in man and other animals.

The antibody fusion proteins may be administered to a patient in need of such treatment in any sterile pharmaceutical carrier that will maintain the solubility and

parasite, rickettsial, bacterial, yeast or fungal antigens expressed on a particular population of microbes may be used in fusion proteins of the invention.

Recombinant nucleic acid molecules that encode the immunoglobulin, linker or anti-microbial peptide may be obtained by any method known in the art. *See, e.g.* Maniatis et al., 1982, Molecular Cloning; A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York or obtained from publicly available clones.

For example, a population of cells known to actively express the peptide is obtained, and total cellular RNA may be harvested therefrom. The amino acid sequence of the peptide sought may be used to deduce the sequence of a portion of the peptide's nucleic acid so as to design appropriate oligonucleotide primers, or, alternatively, the oligonucleotide primers may be obtained from a known nucleic acid sequence which encodes the peptide. The oligonucleotide fragment may then be used in conjunction with reverse transcriptase to produce cDNA corresponding to peptide-encoding nucleotide sequence. Okayama et al., 1987, Methods Enzymol. 154:3-29. The cDNA can then be cloned, and/or portions of the peptide coding region may then be amplified from this cDNA using polymerase chain reaction and appropriate primer sequences. Saiki et al., 1988, Science 239:487-491. Alternatively, specific nucleic acid sequences encoding the anti-microbial peptides disclosed in this application are available in the references cited above and in the sequence listings presented below.

In preferred embodiments of the invention, a recombinant vector system was created to accommodate sequences encoding the anti-microbial peptide in the correct reading frame with the linker peptide and immunoglobulin. For example, and not by way of limitation, sequential PCR reactions were done to add on portions of the fusion protein described above. In the first reaction the linker peptide was added upstream of the variable region of the heavy chain. The second PCR reaction added the anti-microbial peptide upstream from the peptide. In the final reaction, a signal peptide was added to the 5' flanking region of the anti-microbial peptide gene to facilitate the secretion of the fused molecule from a cell transformed with the recombinant vector. Once the proper

antibody fusion protein gene. In the third method, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions which include antibiotic resistance and transformation phenotype caused by the insertion of foreign genes in the vector. For example, if the antibody fusion gene was inserted so as to interrupt the marker gene sequence of the vector, recombinant constructs containing the antibody fusion gene insert can be identified by the absence of the marker gene function. Alternatively, gene additions that confer identifiable marker phenotypes in the transformed cell can be employed. In the present invention, successfully incorporated constructs were discovered with the observation that the cells were resistant to drugs such as histidinol or mycophenolic acid.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. The expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus, adenovirus or retroviral based vectors; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

#### 4. Analysis of Targeted Antimicrobial Fusion Proteins

The fusion proteins of the present invention may be produced by cells transformed as previously described, and may be collected using any technique known in the art, including, but not limited to, affinity chromatography using target antigen or antibody specific for any portion of the fusion protein including, for example, anti-idiotype antibody. The activity of the fused anti-microbial peptide may be confirmed using biological assays which detect whether the antibody is antigen specific and whether the anti-microbial peptide is effective in destroying the microbe or inhibiting its growth.

In a specific embodiment of the invention, the specificity of the antibody-based fusion protein to *S. mutans* was measured using both fluorescent microscopy and flow

cytometry. The desired targeting of the fused anti-microbial peptide was confirmed by observing that the antibody fusion protein results in the destruction of *S. mutans* using an anti-microbial peptide concentration that would normally not affect the microbe.

**Examples:**

1. Construction and Expression of a Histatin 5 and Dhvar 1/SWLA3 Chimeric Antibody Fusion Protein With Activity Against *S. mutans*.
  - a. Construction of an expression vector for an antibody-based fusion protein

The construct that is ultimately cloned into an IgG<sub>1</sub> expression vector and leads to the expression of the targeted antimicrobial fusion protein was assembled according to the following method (see FIG. 1). The construct was assembled using sequential PCR and restriction enzymes techniques. The recognition sequence of the of the fusion protein was derived from heavy chain sequences of SWLA3, produced by hybridoma ATCC HB 12558. *See* Shi, United States patent 6,231,857, the disclosure of which is incorporated by reference, and United States serial numbers 09/378,577 and 09/881,823. Sequences that code on expression for Histatin 5 or dhvar1 were inserted upstream of the variable region of the heavy chain of SWLA3. The amino acid sequences used for histatin 5 and dhvar 1 are listed below:

Histatin 5 (SEQ ID NO: 2) DSHAKRHHGY KRKFHEKHHS HRGY

Dhvar 1 (SEQ ID NO: 6) KRLFKELKFS LRKY.

The source signal peptide was added upstream of the histatin 5 or dhvar1, and a glycine/serine linker (SEQ ID NOS: 3 and 7) was added to separate the fusion protein from the variable region of the heavy chain (VH) of the antibody. See FIG. 3 for the nucleic acid and predicted amino acid sequence for the histatin 5/SWLA3 VH and FIG. 4 for the respective dhvar 1/SWLA3 VH sequences. Sequential PCR reactions were used to complete the construct according to the following method (see FIG. 2 for the nucleic acid sequence of the primers used):

1. In the first PCR reaction a plasmid carrying the VH of SWLA3 was used as the template with primer sets 986+452 (histatin 5) or 989+452 (dhvar1). This reaction replaced the signal peptide in the original gene with the linker peptide at the 5' end of the VH and inserted a restriction site at the 3' end. The products of this reaction were isolated and used a template in the second PCR reaction.
2. Using primer sets 987+452 (histatin 5) or 990+452 (dhvar1) in the second PCR reaction added the anti-microbial peptide upstream from the linker peptide. The restriction site at the 3' end was maintained. The products from this reaction were isolated and used as the template in the third PCR reaction.
3. With primer sets 988+452 (histatin 5) or 991+452 (dhvar1) a signal peptide and restriction site were added upstream from the anti-microbial peptide. The restriction site at the 3' end was maintained. Products from the third PCR were isolated.
4. Isolated products from the third PCR reaction were then cloned into Invitrogen's PCR2.1 vector via TOPO Cloning Kit and sequenced.
5. After the sequences of the two clones were confirmed, the inserts were moved into the IgG<sub>1</sub> PCR expression vector (pAH 4604) as an NheI/EcoRV fragment.
6. The final expression vectors for the histatin 5 and dhvar 1 antibody fusion proteins were named pAH 5993 and pAH 5994 respectively.

PCR conditions used were:

1. Denature @ 94°C for 40 sec.
2. Anneal @ 60°C for 40 sec.
3. Extend @ 72°C for 40 sec.
4. Amplify for 30 cycles
5. Final Extension at 72°C for 10 min.

FIG. 3 shows the nucleic acid sequence encoding the histatin 5 fusion to VH SWLA3 and predicted amino sequence (SEQ ID NOS: 1 and 4) and FIG. 4 which shows

the nucleic acid sequence encoding the dhvar1 fusion to VH SWLA3 and predicted amino sequence (SEQ ID NOS: 5 and 8). In the figures, the bold sequences represent the corresponding anti-microbial peptides, the underlined sequences represent the glycine/serine linker, and the single bolded underlined base in each sequence represents a silent point mutation. In the original sequence disclosed in Shi et al. Shi et al. United States serial number 09/881,823, the base is guanine.

The variable region of the light chain (VL) from SWLA3 was cloned into a human kappa expression vector named 5940 pAG according to the method described in Shi et al. United States serial number 09/881,823. Briefly,

- (i) DNA was prepared from the expression vectors and from the plasmid containing the correct VL. See Current Protocols in Immunology, Section 2.12.1 (1994) for detailed information about the vectors that express the light and heavy chain constant regions.
- (ii) The expression vector was digested with the appropriate restriction enzyme. The digests were then electrophoresed on an agarose gel to isolate the appropriate sized fragment.
- (iii) The plasmid containing the cloned VL region was also digested and the appropriate DNA fragment containing the VL region was isolated from an agarose gel.
- (iv) The VL region and expression vector were then mixed together, T4 DNA ligase was added and the reaction mixture was incubated at 16°C over night.
- (v) Competent cells were transfected with the VL ligation mixture and the clones expressing the correct ligation sequence were selected. Restriction mapping was used to confirm the correct structure.

b. Transfected Eukaryotic Cells

of 0.02 mg/ml Poly-L-lysine. These antigen-coated plates were incubated overnight at 4° C in a moist box then washed 3 times with PBS and blocked with 0.5% fetal calf serum in PBS and stored at 4° C. 100 µl of chimeric antibodies at 50 µg/ml were added to the appropriate wells of the antigen plates, incubated for 1 h at RT, washed 3 times with PBS-0.05% Tween 20, and bound antibody detected by the addition of polyvalent goat-anti-human IgG antibody conjugated with alkaline phosphatase diluted 1:10<sup>3</sup> with PBS-1% fetal calf serum. After the addition of the substrate, 1 mg/ml p-nitrophenyl phosphate in carbonate buffer (15 mM Na<sub>2</sub>CO<sub>3</sub>, 35 mM NaH<sub>2</sub>CO<sub>3</sub>, 10 mM MgCl<sub>2</sub> pH 9.6), the color development after 15 min was measured in a EIA reader at 405 nm. "+" means OD405>1.0; "-" means OD405<0.05. The negative control is <0.05. The results are given in Table 1.

TABLE 1

| Oral Bacteria                   | Strains    | Hitstatin 5/SWLA3<br>Fusion Antibodies | Dhvar 1/SWLA3<br>Fusion Antibodies |
|---------------------------------|------------|--|------------------------------------|
| <i>S. mutans</i>                | AATCC25175 | +                                      | +                                  |
|                                 | LM7        | +                                      | +                                  |
|                                 | OMZ175     | +                                      | +                                  |
| <i>S. Mitis</i>                 | ATCC49456  | -                                      | -                                  |
| <i>S. rattus</i>                | ATCC19645  | -                                      | -                                  |
| <i>S. sanguis</i>               | ATCC49295  | -                                      | -                                  |
| <i>S. sobrinus</i>              | ATCC6715-B | -                                      | -                                  |
| <i>S. sobrinus</i>              | ATCC33478  | -                                      | -                                  |
| <i>L. acidophilus</i>           | ATCC4356   | -                                      | -                                  |
| <i>L. casei</i>                 | ATCC11578  | -                                      | -                                  |
| <i>L. plantarum</i>             | ATCC14917  | -                                      | -                                  |
| <i>L. salivarius</i>            | ATCC11742  | -                                      | -                                  |
| <i>A. actinomycetemcomitans</i> | ATCC33384  | -                                      | -                                  |
| <i>A. naeslundi</i>             | ATCC12104  | -                                      | -                                  |
| <i>A. viscosus</i>              | ATCC19246  | -                                      | -                                  |
| <i>Fusobacterium nucleatum</i>  | ATCC25586  | -                                      | -                                  |
| <i>Porphyromonas gingivalis</i> | ATCC33277  | -                                      | -                                  |

The fusion proteins showed both specificity and antimicrobial efficacy against *S. mutans*. Like the monoclonal antibodies from which they are derived, the fusion proteins bind specifically to *S. mutans*. They also have anti-bacterial efficacy against the bacteria, but are effective at a much lower concentration than histatin 5 alone. This observation suggests that the recognition sequence is responsible for specific binding between the fusion protein and *S. mutans*, which locally enhances the concentration of histatin 5 at the bacterial cell surface. At the concentration at which the fusion protein showed antibacterial efficacy, the fusion proteins showed no inhibitory effect on other bacteria or host cells. Accordingly, these results suggest that the basic design described herein may be useful for generating antibody-based fusion proteins for treatment of other infections and infestations.

While various embodiments are disclosed in this application, it is apparent that the invention can be altered to provide other embodiments that utilize the composition and process of the invention. Therefore it will be appreciated that the scope of the invention is to be defined by the claims appended hereto rather than by the specific embodiments and examples that have been disclosed for the purposes of illustrating and explaining the invention.